Anterior Uveitis Clinical Trial
Official title:
The Contribution of Altered Aqueous Dynamics in the Development of Raised Intraocular Pressure in Patients With Uveitis
Uveitis is a disease that affects over 2 million people around the globe, and can ultimately
lead to blindness. The proportion of patients with uveitis who become blind has not been
reduced over the past 30 years, and this is therefore an area that demands further research.
One of the major causes of blindness in uveitic patients is the development of uveitic
glaucoma, which occurs in 10-20% of uveitic eyes. This is likely to occur for reasons related
to the uveitis itself, but can also be caused as a side effect of the corticosteroids used to
treat uveitis. The raised IOP in uveitis is more difficult to treat than other types of
glaucoma.
To enable more effective treatment of uveitic glaucoma, the investigators need to understand
more clearly the mechanisms which underlie this process. The investigators therefore propose
a study to examine the contribution of altered aqueous dynamics to the development of raised
IOP in uveitis.
The investigators propose to undertake a cross-sectional observational study of patients with
recurrent idiopathic acute anterior uveitis, to determine the relative contributions of
altered aqueous production and drainage to the development of raised IOP in these patients.
Methods
Study Design A cross sectional observational study
Patient Selection All subjects attending the uveitis and glaucoma clinics at St Thomas'
Hospital will be eligible to be included in the study if they fulfil the inclusion/exclusion
criteria as below.
30 patients will be included from each of these three group of patients: 1) recurrent (> 5
attacks) idiopathic acute anterior uveitic with raised intraocular pressure; 2) recurrent (>
5 attacks) idiopathic acute anterior uveitic without raised intraocular pressure; 3) healthy
age matched volunteers as controls. Patients on glaucoma treatment will be washed out for one
month before measurement.
Examination Schedule and Methods
1. Visual acuity:
Visual acuity is measured before pupil dilation, tonometry, gonioscopy, or any other
technique that could affect vision. Two different techniques are used to measure visual
acuity, including Snellen and ETDRS visual acuity testing. Refraction is performed prior
to formal measurement of visual acuity by either technique.
Subjective Refraction:
It is permissible to use a phoropter or trial frame to determine best-corrected Snellen
visual acuity. The left eye is occluded first. An approximate beginning refraction may
be determined by retinoscopy, automated refraction, or a subjective refraction from a
prior visit. The sphere is refined first. The cylinder is then refined, first the axis
followed by the power. Finally, the sphere is rechecked. The right eye is then occluded,
and the procedure is repeated for the left eye.
If the patient wears contact lenses and has glasses also, he or she is instructed not to
wear the contact lenses on the day of the assessment. Patients unwilling to discontinue
contact lens use after surgery will be excluded from the study. In the event that the
patient either has no glasses or has forgotten the instructions and reported for the
assessment wearing contact lenses, the contact lenses are removed and at least thirty
minutes allowed to elapse before subjective refraction and visual acuity testing is
performed.
ETDRS Visual Acuity:
The logmar visual acuity testing for the Uveitic Glaucoma study has been adapted from
the Early Treatment of Diabetic Retinopathy (ETDRS) at 4 metres. The logmar visual
acuity scale facilitates statistical analysis and simplifies quantification of acuity at
various distances. The right eye is tested with ETDRS logmar chart 1, then the left eye
is tested with ETDRS logmar chart 2. Each chart is hidden from view until the eye being
examined is ready for testing.
Snellen Visual Acuity:
Snellen visual acuity may be measured using any standard visual acuity chart. The same
type of chart must be used throughout the duration of the study. Standardized refraction
is performed prior to Snellen visual acuity testing.
2. Slit lamp biomicroscopy Examination of the anterior segment using slit lamp
biomicroscopy will be performed. Slit lamp biomicroscopy may be performed with any
commercially available instrument, and it is used in a standard fashion starting
anteriorly and working posteriorly.
3. Gonioscopy Gonioscopy is performed with the patient sitting at the slit lamp using
either a Zeiss type four-mirror gonioprism or Goldmann single- or three-mirror lens.
4. Pachymetry Central corneal thickness is measured with ultrasound pachymetry. The right
eye is tested first. A drop of 0.5% proparacaine is instilled for anesthesia. The
patient is asked to look straight ahead at a distant object or fixation target. The
pachymeter probe is lined up with the center of the pupil and slowly advanced until it
contacts the cornea. The probe is withdrawn when an audible signal is made indicating
that a measurement has been recorded. The patient is instructed to blink. The procedure
is repeated to obtain three separate readings, and the investigator records the
measurements. After testing of the right eye is complete, the same technique is applied
to testing of the left eye.
5. Biometry A Carl Zeiss IOL Master will be used to carry out biometry and assess anterior
chamber depth using A-scan ultrasound. This is a non-contact examination technique.
6. Fundoscopy A dilated fundus examination is performed. After pupil dilation with
appropriate mydriatics, the optic nerve and posterior pole are examined at the slit lamp
using Volk 90 diopter, 78 diopter, or 60 diopter lens.
7. Flurophotometry The night before (10 PM) the fluorophotometric scans, participants will
self-administered 3 to 6 drops of fluorescein sodium 2% (Minims, Bausch&Lomb, UK)
topically into both eyes at 5 minutes interval depending on their age (age 25 years or
younger, 5-6 drops; age 26 to 35 years, four drops; over 35 years of age, three drops).
Fluorophotometry will be performed in both eyes using a scanning ocular fluorophotometer
from 9AM to 12PM (FM-2, Fluorotron Master Ocular Fluorophotometer; OcuMetrics, Mountain
View, California). The aqueous turnover protocol will be used to calculate the aqueous
flow rate. Duplicate or triplicate scans will be collected and repeated at 1 hour
intervals for 4 measurements to determine the aqueous flow rate (Ft). Following each set
of scans, IOP will be measured using pneumatonometry (Model 30 Classic, Reichert
Ophthalmic Instruments, Depew, New York). IOP will be recorded as the arithmetic mean of
a total of 12 measurements per eye: 3 measurements every hour alternating between eyes.
8. Tonography Tonographic outflow facility (C) will be performed using an electronic
Schiøtz tonographer (Model 720, Berkeley Bioengineering Inc, USA) at 10AM. The facility
of outflow will be calculated from the rate of decay of intraocular pressure in the
supine position during application of a recording Schiøtz tonometer over a period of 4
minutes with a standard 5.5 gram weight. The "R" values of the curve at every 30-second
time point will be manually entered into the McLaren tonography computer program. The
program fits a second-degree polynomial by least squares to the nine data points and
determines the best-fit values for time 0 and time 4 minutes by extrapolation.
Uveoscleral outflow will be calculated using the Goldmann's equation with an assumed
episcleral venous of 8, 9, 10 or 11 mmHg. Ft is the rate of aqueous humor formation, C
is the tonographic facility of outflow, IOP is the intraocular pressure, Pv is the
episcleral venous pressure and Fu is the uveoscleral outflow.
Ft = C (IOP-Pv) +Fu Fu = Ft-C (IOP-Pv)
Only one randomly (Excel random number generator) chosen eye per participant will be
included in the data analysis when both eyes fulfilled the inclusion criteria.
9. Visual fields Quantitative automated perimetry is performed using the Humphrey Field
Analyzer. Visual field testing is performed before tonometry, gonioscopy, or any other
technique that could affect vision. A visual field should be attempted in any eye that
has sufficient vision to permit finger counting at two feet. Eyes with poor central
vision may have an intact, off-center island of vision which may be measured with
perimetry.
A 24-2 threshold test is performed in all patients using a size III white stimulus. Visual
field testing may be performed with the Swedish Interactive Thresholding Algorithm (SITA) or
full threshold strategy, but the same testing strategy must be used throughout the duration
of the study. The pupil diameter should be 3 mm or greater before visual field testing is
undertaken, and this may require pharmacologic dilation. Standardized refraction is performed
to determine the patient's distance refraction and best-corrected visual acuity prior to
visual field testing. The age appropriate plus lens is added to the distance refraction.
Patient education is provided, and the instrument is set up for the test. The technician
should monitor the patient during testing. Visual fields are performed preoperatively (within
one month of enrollment in the study) and annually thereafter. Copies of all visual fields
are faxed to the Statistical Coordinating Center for evaluation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00476593 -
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
|
N/A | |
Recruiting |
NCT01486693 -
Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis
|
N/A | |
Recruiting |
NCT01156285 -
Acute Anterior Uveitis: Psychic Burden and Pain
|
N/A | |
Terminated |
NCT00333996 -
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
|
Phase 2/Phase 3 | |
Completed |
NCT00405496 -
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
|
Phase 2 | |
Completed |
NCT02764697 -
Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
|
Phase 4 | |
Completed |
NCT01376362 -
Topical Interferon Gamma for Macular Edema Secondary to Uveitis
|
Phase 1/Phase 2 | |
Recruiting |
NCT00407316 -
Quality of Life and Visual Function in Uveitis Patients
|
Phase 0 | |
Completed |
NCT02725177 -
Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
|
N/A | |
Completed |
NCT01647529 -
Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis
|
N/A | |
Completed |
NCT00823173 -
Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis
|
Phase 2 | |
Completed |
NCT02517619 -
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis
|
Phase 3 | |
Completed |
NCT01505088 -
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
|
Phase 3 | |
Completed |
NCT02879084 -
Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis
|
||
Completed |
NCT01154010 -
PEMF: an Adjunct Therapy for Anterior Uveitis
|
N/A | |
Completed |
NCT00130637 -
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
|
Phase 2 | |
Completed |
NCT00406887 -
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
|
Phase 3 | |
Completed |
NCT00876434 -
Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti
|
Phase 1 |